# Can a GLP-1 Pill Revive Novo Nordisk? | Prof G Markets Source: https://www.youtube.com/watch?v=Z70I9ASCU7A Recap page: https://rapidrecap.app/video/Z70I9ASCU7A Generated: 2026-01-07T15:01:20.631+00:00 --- ## Quick Overview Novo Nordisk's GLP-1 oral pill, Wegovy, which gained FDA approval on December 23, 2025, is experiencing massive adoption, with 1 in 8 American adults currently using GLP-1s, signaling a major shift in obesity treatment that may eventually challenge the market dominance of injectable GLP-1s like Eli Lilly's Zepbound. **Key Points:** - The FDA approved the oral GLP-1 pill, Wegovy, for weight loss on December 23, 2025, marking the first daily oral medication of its kind in the US. - Current usage of GLP-1s is high, with 1 in 8 American adults (over 40 million people) currently using them as of 2022. - The oral version of the drug is priced between $149 and $299 per month, a fraction of the price of injectables, which may spur adoption, especially since roughly one-third of adults fear needles. - The oral GLP-1 market is predicted to be massive, potentially exceeding $100 billion in market cap, with Novo Nordisk's oral version being a major driver. - Eli Lilly's Zepbound (an injectable GLP-1) is currently the leader, but Novo Nordisk's oral version competes by offering a non-needle alternative, potentially disrupting the market share. - The analyst Jared Holtz suggests the oral format is a significant factor in adoption, as many patients fear needles, leading to a potential 'reverse-hype cycle' where the oral drug gains traction despite the initial focus on injectables. - The success of Novo Nordisk's oral GLP-1 is seen as a major development that could pressure competitors like Eli Lilly and potentially lead to further large deals in the sector. ![Screenshot at 23:50: The host displays a graphic stating that 1 in 8 Americans currently use GLP-1s, highlighting the massive existing patient base for obesity treatments.](https://ss.rapidrecap.app/screens/Z70I9ASCU7A/00-23-50.jpg) **Context:** The video features an interview between Ed Elson (host of Prof G Markets) and Jared Holtz, Healthcare Equity Strategist at Mizuho, discussing recent market developments, primarily focusing on Novo Nordisk's FDA approval of Wegovy as an oral pill for weight loss. The conversation also touches upon the broader GLP-1 market, including competitors like Eli Lilly's Zepbound, the high rate of needle phobia affecting patient adherence, and the expected market impact of a convenient oral alternative. ## Detailed Analysis The video details the recent FDA approval of Novo Nordisk's oral GLP-1 drug, Wegovy, for weight loss on December 23, 2025, noting it is the first daily oral medication of its kind in the US. Host Ed Elson speaks with analyst Jared Holtz of Mizuho about the implications. Holtz points out that the market for GLP-1 drugs, currently dominated by injectables like Eli Lilly's Zepbound, is massive, with expectations that the oral versions will drive significant growth, possibly exceeding $100 billion in market cap. A key factor driving the oral pill's potential success is patient preference, as 63% of US adults experience some level of needle phobia, leading them to actively avoid injections like the weekly GLP-1s. The oral Wegovy pill is priced significantly lower than injectables, between $149 and $299 per month, which Holtz suggests will allow patients to start on lower doses and potentially stay on treatment longer, even if the overall efficacy isn't drastically different initially. Holtz believes this oral format revolutionizes accessibility and adoption, potentially leading to a market share shift away from injectable leaders like Eli Lilly. ### Market News & GLP-1 Landscape - FDA approved Wegovy oral pill (Dec 23, 2025) for weight loss - This pill is the first daily oral GLP-1 medication in the US - Novo Nordisk's stock rose 5% following the announcement - The oral pill is priced $149-$299/month, a fraction of the injectable cost. ### Patient Adoption & Needle Phobia - 1 in 8 Americans (over 40 million) currently use GLP-1s (Source: NPR 2022) - 63% of adults experience needle phobia, often avoiding necessary injections like GLP-1s. ### Competitive Dynamics - Eli Lilly's Zepbound (injectable) is the current leader, but the oral format creates immediate competition - Novo Nordisk's oral drug is expected to take significant market share, potentially causing a 'reverse hype cycle' where oral adoption outpaces initial injectable growth. ### Expert Insight (Jared Holtz) - Holtz suggests the oral format addresses a significant barrier to entry (needle phobia) - He believes the oral version will be a major success and that the market will see more oral GLP-1s and similar AI-driven health products soon. ![Screenshot at 00:01: The host introduces the topic of the day with the figure "120M" displayed on screen, likely referencing a large financial or user metric.](https://ss.rapidrecap.app/screens/Z70I9ASCU7A/00-00-01.jpg) ![Screenshot at 00:31: A graphic displays the performance of major indices: S&P 500, Nasdaq, and Dow, all showing upward arrows, indicating market gains.](https://ss.rapidrecap.app/screens/Z70I9ASCU7A/00-00-31.jpg) ![Screenshot at 00:57: A large banner for the Consumer Electronics Show \(CES\) 2026 in Las Vegas is shown, indicating a shift in discussion topic.](https://ss.rapidrecap.app/screens/Z70I9ASCU7A/00-00-57.jpg) ![Screenshot at 01:08: A news headline overlay states: "Jensen Huang Says Nvidia's New Vera Rubin Chips Are in 'Full Production'", referencing a key announcement from CES.](https://ss.rapidrecap.app/screens/Z70I9ASCU7A/00-01-08.jpg) ![Screenshot at 01:39: The host is joined by guest Alex Heath, Author/Host of the Sources Newsletter and ACCESS Podcast, for discussion.](https://ss.rapidrecap.app/screens/Z70I9ASCU7A/00-01-39.jpg)